A5027634537- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- Breast Lesions and Carcinomas
- Cancer-related Molecular Pathways
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Cancer survivorship and care
- Monoclonal and Polyclonal Antibodies Research
- MicroRNA in disease regulation
- Cancer Risks and Factors
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- Peptidase Inhibition and Analysis
- Cancer, Hypoxia, and Metabolism
- Cancer-related molecular mechanisms research
- Genomics and Chromatin Dynamics
- Family Support in Illness
- PI3K/AKT/mTOR signaling in cancer
- Cancer Cells and Metastasis
- Cancer and Skin Lesions
- Epigenetics and DNA Methylation
- Multiple Myeloma Research and Treatments
Nagoya City University
2016-2025
Mizuho (Japan)
2013-2025
Nagoya City University Hospital
2011-2024
Nagoya University
2022
Japan Cancer Society
2020-2021
Norsk Elektro Optikk (Norway)
2021
Nagoya Institute of Technology
2018-2020
Aichi Cancer Center
2004-2019
Hitachi (Japan)
2014-2019
Osaka National Hospital
2011-2019
Abstract Expression levels of estrogen receptor (ER) α govern estrogen-dependent growth, response to endocrine therapy, and prognosis in ERα-positive breast cancer. Multiple mechanisms involved altering ERα gene expression cancer have been identified, including amplification as well transcriptional silencing by DNA methylation CpG islands within the promoter mutations open reading frame ERα. However, tissues differ widely among patients, frequently change during disease progression systemic...
Human epidermal growth factor receptor 3 (HER3) is broadly expressed in breast cancer; high expression associated with an adverse prognosis. Patritumab deruxtecan (HER3-DXd) investigational HER3-targeted antibody-drug conjugate that being evaluated as a novel treatment HER3-expressing advanced cancer the U31402-A-J101 study.Adults disease progression on previous therapies were eligible. Patients dose-escalation, dose-finding, and dose-expansion parts received HER3-DXd 1.6-8.0 mg/kg...
Survivin, a new member of the inhibitor-of-apoptosis (IAP) family, has been reported to be expressed in many cancers but not differentiated normal tissue. Its expression esophageal cancer, however, reported. We investigated 51 and their adjacent epithelial tissues for mRNA survivin by RT-PCR. The cancer tissue was significantly higher than that (0.211 +/- 0.226 vs. 0.057 0.135, p < 0.0001). pN4 tumors had pN0-3 (p = 0.0093). Fourteen patients with advanced received chemotherapy prior...
Abstract Purpose: The structure and function of chromatin can be altered by modifications to histone. Histone acetylation in vivo is a dynamic reversible process governed histone acetyltransferases (HATs) deacetylases (HDACs). HDAC6 unique isoform among the HDACs, gene expression pattern study, with cDNA microarray MCF-7 cells, showed late responsive, estrogen induced, up-regulated. This led us hypothesize that there was link between levels metastatic potential breast cancer also, therefore,...
Significance Whether breast cancer will respond to the antiestrogen tamoxifen is determined by whether cellular proliferation estrogen receptor (ER) α-mediated. As opposed early ductal cancer, which an ERα-rich, proliferating disease, in lobular both ERα and ERβ are abundantly expressed rare. In advanced lost, retained, high. Thus, may be effective pharmaceutical late but not cancer.
Abstract Objective : A needs assessment can be used as a direct index of what patients perceive they need help with. The purposes this study were to investigate the association between patients' perceived and psychological distress and/or quality life (QOL) clarify characteristics with high degree unmet needs. Methods Randomly selected ambulatory female breast cancer participated in study. asked complete Short‐form Supportive Care Needs Survey questionnaire, which covers five domains (health...
The Recurrence Score test is validated to predict benefit of adjuvant chemotherapy. TransNEOS, a translational study New Primary Endocrine-therapy Origination Study (NEOS), evaluated whether results can clinical response neoadjuvant letrozole.NEOS phase 3 trial hormonal therapy ± chemotherapy for postmenopausal patients with ER+, HER2-negative, clinically node-negative breast cancer, after six months letrozole and surgery. TransNEOS had tumors ≥ 2 cm archived core-biopsy samples taken before...
1002 Background: Patritumab deruxtecan (HER3-DXd) is a novel, investigational ADC composed of human anti-HER3 monoclonal antibody covalently bound to topoisomerase I inhibitor payload via stable tetrapeptide-based cleavable linker. Here we report updated safety and efficacy data from this ongoing study (U31402-A-J101; NCT02980341; JapicCTI-163401) HER3-DXd in pts with previously treated MBC. Methods: U31402-A-J101 phase 1/2, multicenter, open-label, first-in-human HER3-expressing MBC (N =...
The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer were updated to the 2022 edition through a process started in 2018. guidelines consist 12 background questions (BQs), 33 clinical (CQs), and 20 future research (FRQs). Multiple outcomes including efficacy safety selected each CQ, then quantitative qualitative systematic reviews conducted determine strength evidence recommendation, which was finally determined voting among designated...
In the primary analysis of open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared (TC) in patients human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall (OS) at median follow-up 25.8 months. Patients who have previously received pertuzumab-containing...
Many laboratories are currently evaluating the usefulness of determination HER2, p53, and Ki67 proliferation indices using immunohistochemical techniques in cancer. Although available studies suggest that these factors might indeed be helpful making treatment decisions cancer patients, their clinical is still controversial. Expression was examined by immunohistochemistry samples breast tissue from 506 patients with invasive ductal carcinoma, obtained between 1981 1999 (median follow up...
Few studies have investigated the prevalence of unmet needs among advanced or recurrent breast cancer patients in Asian countries and little is known about relation between their psychological distress/quality life. The participants (n = 87) comprised randomly selected ambulatory female with attending Outpatient Department Oncology, Immunology Surgery Nagoya City University Hospital. were asked to complete self-administered questionnaires assessing level physical symptoms, supportive care...
MicroRNAs have emerged as a new class of non-coding genes involved in regulating cell proliferation, differentiation and viability. Recent studies identified miR-210 one set hypoxia-regulated microRNAs demonstrated direct regulatory role HIF-1 alpha for its transcription. Here, we assessed expression Japanese triple-negative breast cancers determined clinical significance. TaqMan MicroRNA assays were performed on 161 samples cancer tissue (58 103 estrogen receptor positive/HER2 negative)....
Abstract Purpose We present the English version of The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment breast cancer, 2018 edition. Methods JBCS formed a task force to update Guidelines, 2015 edition, according Minds Handbook Guideline Development 2014. First, we set multiple outcomes each clinical question (CQ). Next, quantitative or qualitative systematic review was conducted outcomes, and strength recommendation CQ taken into consideration during...
Abstract The Japanese Breast Cancer Society Clinical Practice Guidelines are published as timely guidance on clinical issues in breast cancer treatment Japan. In the recent edition of these guidelines, we addressed a new question 34 (CQ 34, systemic part) “Is trastuzumab deruxtecan recommended for patients with unresectable or metastatic HER2-low cancer?” and future research 7 (FRQ 7, pathological diagnosis “How is diagnosed indication deruxtecan?”. These questions address use who have...